CTMX CytomX Therapeutics Inc.

9.28
-0.14  -1%
Previous Close 9.41
Open 9.44
Price To Book 6.11
Market Cap 426,167,342
Shares 45,923,205
Volume 544,868
Short Ratio
Av. Daily Volume 646,602
Stock charts supplied by TradingView

NewsSee all news

  1. CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

    SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  2. CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  3. CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

    SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  4. CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

    - 7 Abstracts Highlighting CytomX's Novel Probody Platform Selected for Oral and Poster Presentations - SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a

  5. CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial has been terminated - March 30, 2020.
PROCLAIM-CX-072-002
Solid tumors
Phase 1 initial data to be presented at ASCO May 29, 2020.
BMS-986249 and nivolumab (ASCO)
Solid Tumors or Lymphomas
Phase 1 initial data due 2021. Enrolment has been paused due to COVID-19.
CX-2009 - PROCLAIM
Solid tumors
Phase 1 presentation at ASCO May 29, 2020.
PROCLAIM-CX-2029 (ASCO)
Solid tumors / diffuse large B-cell lymphoma (DLBCL)
Phase 1/2a trial ongoing.
BMS-986288 and nivolumab
Solid tumors

Latest News

  1. CytomX Therapeutics Announces Details of Presentations at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program

    SOUTH SAN FRANCISCO, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  2. CytomX Therapeutics Announces First Quarter 2020 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., May 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  3. CytomX Therapeutics to Present at the 2020 Bank of America Securities Health Care Conference

    SOUTH SAN FRANCISCO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  4. CytomX Therapeutics Announces Presentations at the 2020 American Society of Clinical Oncology Virtual Scientific Program

    - 7 Abstracts Highlighting CytomX's Novel Probody Platform Selected for Oral and Poster Presentations - SOUTH SAN FRANCISCO, Calif., April 29, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a

  5. CytomX Therapeutics Appoints Halley E. Gilbert to Board of Directors

    SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  6. CytomX Therapeutics to Announce First Quarter 2020 Financial Results

    SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  7. CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline

    Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million Payment to CytomX Clinical Studies for CX-2009 and CX-072 impacted by

  8. CytomX Therapeutics Announces New Employment Inducement Grant

    SOUTH SAN FRANCISCO, Calif., March 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  9. CytomX Therapeutics and Astellas Announce Strategic Collaboration to Develop Probody® T-Cell Engaging Bispecific Therapies for Treatment of Cancer

          - Collaboration to Utilize CytomX's Novel Probody® Technology Platform for CD3 Bispecific Targets -      - CytomX to Receive $80 Million Upfront Payment and      Ability to Exercise Option for U.S.

  10. CYTOMX THERAPEUTICS ANNOUNCES APPOINTMENT OF CARLOS CAMPOY AS CHIEF FINANCIAL OFFICER

    SOUTH SAN FRANCISCO, Calif., March 23, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  11. CytomX Therapeutics Announces New Employment Inducement Grant

    SOUTH SAN FRANCISCO, Calif., March 16, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  12. CytomX Therapeutics Announces Full-Year 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  13. CytomX Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference

    SOUTH SAN FRANCISCO, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  14. Bristol-Myers Squibb Advances CytomX Therapeutics' Anti-CTLA-4 Probody Therapeutic BMS-986249 into Randomized Cohort Expansion (Part 2a) of Ongoing Clinical Trial

    Expansion Phase to Evaluate CTLA-4-Directed Probody® Therapeutic in Combination with Opdivo® in Metastatic Melanoma  Bristol-Myers Squibb also Advances BMS-986288 into a Separate Phase 1/2a Clinical Trial SOUTH SAN

  15. CytomX Therapeutics to Announce Fourth Quarter 2019 Financial Results

    SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  16. CytomX Therapeutics Announces New Employment Inducement Grant

    SOUTH SAN FRANCISCO, Calif., Feb. 07, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  17. CytomX Therapeutics Appoints Alison L. Hannah, M.D. as Chief Medical Officer

    SOUTH SAN FRANCISCO, Calif., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  18. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Jan. 17, 2020 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  19. CytomX Therapeutics Provides Updates on Lead Clinical Programs and 2020 Portfolio Outlook

     - Wholly-Owned anti-PD-L1 and anti-CD166 Programs Entering Phase 2 Studies – - Partnered Clinical Programs Advancing - - Multiple Updates Anticipated Across Portfolio in 2020 - SOUTH SAN FRANCISCO, Calif.,

  20. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 17, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  21. CytomX Therapeutics Announces New Employment Inducement Grants

    SOUTH SAN FRANCISCO, Calif., Dec. 06, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  22. CytomX Therapeutics to Present at Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Nov. 11, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  23. CytomX Therapeutics Announces Third Quarter 2019 Financial Results and Provides Business Update

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  24. CytomX Therapeutics Announces Initiation of Phase 2 Clinical Trial Evaluating the Anti-PD-L1 Probody CX-072 in Combination with YERVOY® in Patients with Relapsed or Refractory Melanoma

    SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody

  25. CytomX Therapeutics Announces Appointment of Amy C. Peterson, M.D. as Chief Development Officer

    -Industry Veteran Joins to Advance Maturing Platform and Pipeline to Next Phase of Development- -Product Development Team Further Strengthened with Appointment of Glenn Michelson, M.D., as Vice President, Clinical

  26. CytomX Therapeutics to Present at Upcoming Healthcare Conferences

    SOUTH SAN FRANCISCO, Calif., Aug. 28, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody